A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers
Ocellaris Pharma, Inc.
Ocellaris Pharma, Inc.
Fusion Pharmaceuticals Inc.
Bolt Biotherapeutics, Inc.
NuCana plc
Formation Biologics
Numab Therapeutics AG
Seagen Inc.
Sotio Biotech Inc.
Novartis
Fate Therapeutics
Genmab
Oncorus, Inc.
Nektar Therapeutics
Calithera Biosciences, Inc
Rubius Therapeutics
Eli Lilly and Company
Tocagen Inc.
Celldex Therapeutics
AbbVie